A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
Eli Lilly and Company
Bicara Therapeutics
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
DEKA Biosciences
Merck Sharp & Dohme LLC
Carisma Therapeutics Inc
Eli Lilly and Company
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
Second Affiliated Hospital, School of Medicine, Zhejiang University
ADC Therapeutics S.A.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
OHSU Knight Cancer Institute
Corvus Pharmaceuticals, Inc.
Emory University
Fate Therapeutics
M.D. Anderson Cancer Center
Fate Therapeutics
Xencor, Inc.
Incyte Corporation
Washington University School of Medicine